Skip to content

Localized Therapeutics for the Treatment of Gastrointestinal Disorders

Localized Therapeutics for the Treatment of Gastrointestinal Disorders

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02290665
Enrollment
18
Registered
2014-11-14
Start date
2015-01-30
Completion date
2015-09-28
Last updated
2018-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Keywords

enema

Brief summary

The purpose of this study is to determine the patient preference for a biocompatible thermosensitive solution-gel versus water or saline (liquid) enema. The thermosensitive solution-gel is comprised of poloxamer, an inactive compound that is designated as GRAS (generally recognized as safe) by FDA. It could subsequently be used as a medium for drug delivery. The poloxamer (gel) is administered to study participants in order to assess preference and proximal distribution.

Interventions

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Generally healthy * Age 18 to 70 years old * Non-pregnant

Exclusion criteria

* GI complaints * Pregnancy * Patients with previous colonic surgery or current bowel injury or obstruction * Allergies to contrast

Design outcomes

Primary

MeasureTime frame
Patient preference, as assessed by questionnaireUp to 3 hours post-administration

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026